Low muscle strength strong prognostic factor than muscle mass in GI & HBP cancers
Written By : Dr.Niharika Harsha B
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-08-30 04:00 GMT | Update On 2022-08-30 06:22 GMT
Advertisement
A new study has revealed that low muscle strength was a stronger prognostic factor than low muscle mass in patients with gastrointestinal and hepatobiliary–pancreatic cancer. The study was published in the journal 'Nutrition.'
In patients with gastrointestinal (GI) and hepatobiliary-pancreatic (HBP) cancers, Sarcopenia has been reported as a prognostic risk factor. Hence, researchers conducted a study to investigate whether the loss of muscle mass or the loss of strength is a stronger prognostic factor in GI & HBP cancers. Based on the survival outcome in patients with GI and HBP cancers, they explored the cutoff values of skeletal muscle mass index (SMI) and handgrip strength (HGS).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.